

Amend the claims as follows:

154.4 (Amended Once) A therapeutic method for controlling thrombosis and decreasing blood hypercoagulation and hemorrhaging risks in a patient which comprises administering to the patient in an antithrombotic effective amount, a composition which comprises a therapeutically acceptable carrier and heparinic mucopolysaccharide fractions having constituents of a molecular weight not in excess of about 10,000 daltons, which fractions have (1) a mixture of lower molecular weight fractions in the range of about 2,000 to about 4,000 daltons with higher molecular weight fractions of a molecular weight in the range of about 4,000 to about 10,000 daltons, (2) a Yin-Wessler of at least 40, and (3) a ratio of Yin-Wessler to USP titer in the range of 3 to 5, and the physiologically acceptable salts thereof, which mixture of fractions have improved antithrombotic activity in vivo which is higher than that of heparin and a whole anticoagulation activity lower than that of heparin, and said method controlling thrombosis by selectively inhibiting coagulation factor Xa while also having a whole anticoagulation effect which is slower and lower than that of heparin.

Claim 5-10
161. (Amended Once) A therapeutic composition for controlling thrombosis and decreasing hemorrhaging and of blood hypercoagulation risks which comprises a therapeutically

9²
acceptable carrier and heparinic mucopolysaccharide fractions having constituents of a molecular weight not in excess of about 10,000 daltons, which fractions have (1) a mixture of lower molecular weight fractions in the range of about 2,000 to about 4,000 daltons with higher molecular weight fractions of a molecular weight in the range of about 4,000 to about 10,000 daltons, (2) a Yin-Wessler of at least 40, and (3) a ratio of Yin-Wessler to USP titer in the range of 3 to 5, and the physiologically acceptable salts thereof, which mixture of fractions have improved antithrombotic activity in vivo which is higher than that of heparin and a whole anticoagulation activity lower and slower than that of heparin.

~~claims 12-17~~
Add the following claims:

9³
~~168~~ 169. Heparinic mucopolysaccharide fractions having constituents of a molecular weight not in excess of about 10,000 daltons, which fractions have (1) a mixture of lower molecular weight fractions in the range of about 2,000 to about 4,000 daltons with higher molecular weight fractions of a molecular weight in the range of about 4,000 to about 10,000 daltons, (2) a Yin-Wessler of at least 40, and (3) a ratio of Yin-Wessler to USP titer in the range of 3 to 5, which mixture of fractions have improved antithrombotic activity in vivo which is higher than that of heparin and a whole anticoagulation activity lower than that of heparin, and the physiologically acceptable salts thereof.

~~claim 19~~
4-37

20
170. The heparinic mucopolysaccharides of claim ¹⁶⁸⁻¹⁸~~169~~ in which the lower molecular fractions have a USP titer less than about 10 units per mg.
B

21
171. The heparinic mucopolysaccharides of claim ¹⁶⁸⁻¹⁸~~169~~ wherein the molecular weight is not in excess of about 8,000 daltons.
B

22
172. The heparinic mucopolysaccharides of claim ¹⁶⁸⁻¹⁸~~169~~ which have a USP titer of about 45 units per mg, a Yin-Wessler titer of about 160 units/mg and a ratio of Yin-Wessler to USP titer of about 3.55.
B

93
23
173. The heparinic mucopolysaccharides of claim ¹⁶⁸⁻¹⁸~~169~~ in which fractions below 4,000 have a ratio of Yin-Wessler to USP titer which is at least 10.
B

24
174. The heparinic mucopolysaccharides of claim ¹⁶⁸⁻¹⁸~~169~~ in which fractions of about 4,000 have a ratio of Yin-Wessler to USP titer higher than 11, and the Yin-Wessler is at least 900 units per mg.
B

25
175. The heparinic mucopolysaccharides of claim ¹⁶⁸⁻¹⁸~~169~~ in which fractions have a Yin-Wessler to USP titer ratio higher than 60 and a Yin-Wessler of at least 1,300 units per mg.
B

²⁶
~~176.~~ The heparinic mucopolysaccharides of claim ¹⁶⁸~~169~~
wherein fractions above 4,000 have a USP titer not exceeding
about 15 units per mg and a Yin-Wessler titer in the range of
about 99 to about 160 units per mg.

²⁷
~~177.~~ The heparinic mucopolysaccharides of claim ²⁶~~176~~
wherein the fractions have a ratio of a Yin-Wessler to USP
titer is in the range of about 13 to about 16.

²⁸
~~178.~~ The heparinic mucopolysaccharides of claim ¹⁸~~168~~
wherein fractions have a USP titer that does not exceed about 6
units per mg, a Yin-Wessler titer not less than about 44 units
per mg and the ratio of Yin-Wessler to USP titers is about at
least 9.

²⁹
~~179.~~ The heparinic mucopolysaccharides of claim ¹⁸~~168~~
having low molecular weight fractions with specific affinity
for antithrombin III.

³⁰
~~180.~~ The heparinic mucopolysaccharides of claim ¹⁸~~168~~
in which fractions have 8 to 12 monosaccharide units corresponding
to a molecular weight ranging from about 2,500 to 3,800.

³¹
~~181.~~ The heparinic mucopolysaccharides of claim ¹⁸~~168~~
wherein fractions have a molecular weight range of about 2,000
to about 8,000.

³²
~~182~~¹⁹. The heparinic mucopolysaccharide fractions of claim ~~169~~¹⁹ which are soluble in an aqueous-alcoholic medium, and insoluble in pure alcohol.

³³
~~183~~³³. A therapeutic composition which presents less risks than heparin of blood hypercoagulation and of a host hemorrhaging, which composition has improved antithrombotic activity (anti-X_a activity) and improved selectivity with respect to anti-X_a activity than heparin in vivo and a lower and slower anticoagulation activity than heparin, and which composition comprises a therapeutically acceptable carrier and an antithrombotic effective amount of heparinic mucopoly-saccharide fractions having constituents of a molecular weight not in excess of about 10,000 daltons, which fractions have (1) a mixture of lower molecular weight fractions in the range of about 2,000 to about 4,000 daltons with higher molecular weight fractions of a molecular weight in the range of about 4,000 to about 10,000 daltons, (2) a Yin-Wessler of at least 40, and (3) a ratio of Yin-Wessler to USP titer in the range of 3 to 5, which mixture of fractions have improved antithrombotic activity in vivo which is higher than that of heparin and a whole anticoagulation activity lower than that of heparin, and the physiologically acceptable salts thereof.

34
184. The therapeutic composition of claim ~~183~~³³ in which the lower molecular fractions of the heparinic mucopolysaccharides have a USP titer less than about 10 units per mg.
B

35
185. The therapeutic composition of claim ~~183~~³³ in which the molecular weight of the heparinic mucopolysaccharides is not in excess of about 8,000 daltons.
B

36
186. The therapeutic composition of claim ~~183~~³³ in which the heparinic mucopolysaccharides have a USP titer of about 45 units per mg, a Yin-Wessler titer of about 160 units/mg and a ratio of Yin-Wessler to USP titer of about 3.55.
B

37
187. The therapeutic composition of claim ~~183~~³³ in which fractions of the heparinic mucopolysaccharides below 4,000 have a ratio of Yin-Wessler to USP titer which is at least 10.
B

38
188. The therapeutic composition of claim ~~183~~³³ in which heparinic mucopolysaccharides have fractions of about 4,000 which have a ratio of Yin-Wessler to USP titer higher than 11, and the Yin-Wessler is at least 900 units per mg.
B

39
189. The therapeutic composition of claim ~~183~~³³ in which fractions of the heparinic mucopolysaccharides have a Yin-Wessler to USP titer ratio higher than 60 and a Yin-Wessler of at least 1,300 units per mg.
B

40
190. The therapeutic composition of claim ~~183~~³³ wherein fractions of the heparinic mucopolysaccharides above 4,000 have a USP titer not exceeding about 15 units per mg and a Yin-Wessler titer in the range of about 99 to about 160 units per mg.

3
41
191. The therapeutic composition of claim ~~190~~⁴⁰ wherein the fractions of the heparinic mucopolysaccharides have a ratio of a Yin-Wessler to USP titer is in the range of about 13 to about 16.

42
192. The therapeutic composition of claim ~~183~~³³ wherein fractions of the heparinic mucopolysaccharides have a USP titer that does not exceed about 6 units per mg, a Yin-Wessler titer not less than about 44 units per mg and the ratio of Yin-Wessler to USP titers is about at least 9.

43
193. The therapeutic composition of claim ~~183~~³³ wherein the heparinic mucopolysaccharides have low molecular weight fractions with specific affinity for antithrombin III.

44
194. The therapeutic composition of claim ~~187~~³⁷ wherein fractions of the heparinic mucopolysaccharides have 8 to 12 monosaccharide units corresponding to a molecular weight ranging from about 2,500 to 3,800.